B+
Bull case
30%
Probability
Target price
$21.00
+59.9% vs current
NTLA
Intellia TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$15.00
+14.2% vs current
B-
Bear case
25%
Probability
Target price
$8.50
-35.3% vs current
AI sentiment snapshot
Latest data as of 2026-05-03
Recent news sentiment (30D)
+0.7
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+64.6
Score
AI commentary
T+3 tone is improved but still mixed. Trusted news in the packet tied an initial roughly 25% jump to the HAELO trial win, while the subsequent stock offering at $10.75 introduced a clear dilution overhang; the May 1 anchor of $13.26 implies the stock held above the deal price but below what a clean post-breakout momentum profile would suggest. Headline buzz is high, but no sufficient social coverage was provided and no verified post-print analyst revision set was available from the sources checked, so conviction should stay moderate.
RankAlpha Sentiment Codex - 2026-05-03
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-15catalystHAELO Phase 3 win shifts the story from binary readout risk to data digestion and filing executionHigh impact
Intellia reported that lonvo-z met the HAELO Phase 3 primary and all key secondary endpoints, with an 87% attack reduction versus placebo, favorable safety, and a rolling BLA already initiated; additional clinical detail is expected at EAACI in June, which is the nearest catalyst for whether the market sustains the rerating beyond the initial headline move [#IR-2026-04-27].
2026-09-30eventRolling BLA completion in 2H26 is now the key regulatory checkpointHigh impact
After the April 27 data release, management said it had initiated a rolling BLA submission and continues to target potential U.S. launch in the first half of 2027 if approved. That materially improves the path to first commercialization, but the name remains highly dependent on clean filing execution and review follow-through because lonvo-z now carries most of the equity story [#IR-2026-04-27] [#10-K-2026-02-26].
2026-12-31catalystApril financing extends runway but adds dilution and keeps focus on disciplined portfolio executionHigh impact
The April 30 8-K says the follow-on offering closed with estimated net proceeds of about $194.6 million, preliminary March 31 cash of about $517.2 million, and a runway now expected at least into 2028. That reduces near-term financing stress versus the prior runway view, but it came through meaningful equity dilution and does not remove dependence on lonvo-z approval or successful nex-z restart execution [#8-K-2026-04-30] [#10-K-2026-02-26].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-03 • Updated nightlySource: Internal modelMethodology